2024
- Kallio, HM, Savolainen, K, Virtanen, T, Ryyppö, L, Selin, H, Martikainen, P et al.. Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer. Life Sci Alliance. 2024;7 (6):. doi: 10.26508/lsa.202402658. PubMed PMID:38580393 PubMed Central PMC10997860.
- Pekkarinen, M, Nordfors, K, Uusi-Mäkelä, J, Kytölä, V, Hartewig, A, Huhtala, L et al.. Aberrant DNA methylation distorts developmental trajectories in atypical teratoid/rhabdoid tumors. Life Sci Alliance. 2024;7 (6):. doi: 10.26508/lsa.202302088. PubMed PMID:38499326 PubMed Central PMC10948937.
- Fonseca, NM, Maurice-Dror, C, Herberts, C, Tu, W, Fan, W, Murtha, AJ et al.. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun. 2024;15 (1):1828. doi: 10.1038/s41467-024-45475-w. PubMed PMID:38418825 PubMed Central PMC10902374.
- Kivioja, T, Posti, JP, Sipilä, J, Rauhala, M, Frantzén, J, Gardberg, M et al.. Motor dysfunction as a primary symptom predicts poor outcome: multicenter study of glioma symptoms. Front Oncol. 2023;13 :1305725. doi: 10.3389/fonc.2023.1305725. PubMed PMID:38239655 PubMed Central PMC10794640.
- Warner, EW, Van der Eecken, K, Murtha, AJ, Kwan, EM, Herberts, C, Sipola, J et al.. Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping. Nat Cancer. 2024;5 (1):114-130. doi: 10.1038/s43018-023-00692-y. PubMed PMID:38177459 .
- Sumiyoshi, T, Wang, X, Warner, EW, Sboner, A, Annala, M, Sigouros, M et al.. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. J Natl Cancer Inst. 2024;116 (1):115-126. doi: 10.1093/jnci/djad184. PubMed PMID:37676819 PubMed Central PMC10777679.